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Young children who become infected with Mycobacterium tuberculosis 
are at high risk of developing tuberculous meningitis, one of the most 
lethal forms of tuberculosis, particularly if appropriate treatment 
is delayed.[1] Currently, there are no guidelines or evidence-based 
options for primary prophylaxis for children exposed to extensively 
drug-resistant tuberculosis (XDR-TB).
South Africa (SA) has one of the world’s highest tuberculosis 
incidence rates[2] and KwaZulu-Natal Province one of the world’s 
worst epidemics of XDR-TB.[3] 
We report the case of a mother-child pair with XDR-TB from 
this setting, which ended fatally in both patients, despite what 
appeared to be appropriate chemotherapy with an effective regimen 
of antituberculosis drugs adapted to the drug susceptibility pattern of 
their M. tuberculosis strain.
The patient was identified in an observational study. The 
information was extracted from the patient’s records and family visits 
in 2016 and 2017.
Case report
A 34-year-old HIV-positive mother, treated with a standard 
antiretroviral drug regimen, was successfully treated for tuberculosis 
with first-line drugs in 2005. She developed a second episode of 
pulmonary tuberculosis in 2007. The resistance of the strain to 
previously never-used antituberculosis medications suggested XDR 
reinfection disease. The drug-susceptibility profile (resistance to 
isoniazid, rifampicin, ethambutol, ciprofloxacin, kanamycin and 
streptomycin) guided her treatment. Sputum specimens remained 
culture-positive before and after the uneventful birth of her daughter 
in 2010, despite reported good treatment adherence. 
The child, HIV-uninfected and with unknown bacillus Calmette-
Guérin vaccination status, received primary isoniazid prophylaxis for 
3 months, in line with the national tuberculosis guidelines.[4] At birth, 
a gastric lavage specimen was negative for M. tuberculosis, a chest 
radiograph was normal, and no evidence of congenital tuberculosis 
was present. The child was living with her mother and relatives in a 
township house without implementation of any specific infection-
control measures. No other member of the household was diagnosed 
with tuberculosis.
At the age of 4 months, the infant presented with right 
upper-lobe radiographic consolidation, interpreted as pneumonia. 
A gastric lavage specimen yielded M. tuberculosis, and first-line 
antituberculosis treatment was started (Fig. 1). Two weeks later, 
the isolate showed resistance to isoniazid and rifampicin by the 
GenoType MTBDRplus assay (Hain Lifescience, Germany), but the 
laboratory reported only ‘resistant’, without specifying the mutations. 
Treatment was changed to a regimen containing capreomycin, 
pyrazinamide, terizidone, moxifloxacin and para-aminosalicylic 
acid. The child was then hospitalised. The gastric lavage was repeated 
and yielded an M. tuberculosis isolate phenotypically also resistant to 
ofloxacin, kanamycin and streptomycin. Ethionamide was added to 
the regimen.
The infant was in a good general condition, but vomited repeatedly 
and became pyrexial, which in retrospect might have been the 
first signs of tuberculous meningitis. Amoxicillin/clavulanate was 
administered. At the age of 6 months, she had the first seizure 
and a bulging fontanelle. The sterile cerebrospinal fluid (CSF) 
showed slightly elevated proteins of 1.05 g/L, low glucose of 
1.4 mmol/L, polymorphs 14 cells/μL and lymphocytes 96 cells/μL. 
Carbamazepine, ceftriaxone and a corticosteroid were administered. 
The infant was irritable, febrile and continued vomiting. Three 
weeks later, high-dose isoniazid and clofazimine were added to the 
regimen, as tuberculous meningitis was suspected. At 7 months 
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of age, a computed tomography (CT) scan was interpreted as 
showing multiple tuberculomas around the right ventricle and both 
parietal lobes, meningeal enhancement and early hydrocephalus, 
consolidating the diagnosis of tuberculous meningitis. She was 
deemed unsuitable for a ventriculoperitoneal (VP) shunt, given 
the compensated hydrocephalus. The corticosteroid dose was 
tapered. During the subsequent months of hospitalisation, she 
vomited repeatedly, was pyrexial and irritable, had delayed motor 
development and a decreased body tone. Amoxicillin/clavulanate and 
para-aminosalicylic acid, but not ethionamide, were discontinued 
owing to concerns of medication-associated vomiting and 
diarrhoea. During this time, the child lost weight, catching up only 
months later (Fig. 2). The M. tuberculosis culture of gastric fluid 
converted to negative at the age of 8 months (3 months on XDR-TB 
treatment). Another seizure episode followed 2 months later. After 
8 months on XDR-TB treatment, capreomycin was discontinued, 
and she was discharged from hospital in a fairly good general 
condition, with persistent neurodevelopmental delay. Her lungs 
were clinically and radiographically clear. High-dose isoniazid, 
pyrazinamide, terizidone, ethionamide, moxifloxacin, clofazimine 
and carbamazepine were continued at home under the care of her 
grandmother, with monthly outpatient follow-up. At the age of 16 months, 
she presented with a repeatedly stiff body and increased spasticity. 
The now non-compensated hydrocephalus required a VP shunt. The 
CSF was unremarkable during the implantation. The CT scan showed 
calcifying tuberculomas.
During the following months the child was well, with clinically 
clear lungs, but remained spastic with occasional seizures at home, 
and a general developmental delay of 1 year.
At the age of 26 months, she presented with increased seizure 
frequency and irritability, fever and neck stiffness. The CT scan 
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Fig. 2. Weight (kg) by age (months) of the child from birth to death (solid line) compared with the WHO reference median weight by age for girls (dot-dot-dashed 
line).[15] Circles are points of actual measurements. (XDR = extensively drug resistant; tx = treatment; Dx = diagnosis; CNS = central nervous system; 
TB = tuberculosis; VP = ventriculoperitoneal; WHO = World Health Organization.) 
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requiring revision. Moxifloxacin was changed to levofloxacin for 
unknown reasons. One month later she presented again with fever, 
neck stiffness and lethargy. The CT scan showed that ventricle 
dilatation had increased. The shunt was removed, and an external 
ventricular drain was placed before inserting a new VP shunt when 
the patient was 27 months of age. One week after discharge, the child 
was readmitted with vomiting, seizures, fever and irritability. The 
magnetic resonance imaging (MRI) findings at the age of 28 months 
were interpreted as tuberculous meningitis and ependymitis with 
obstructive hydrocephalus due to a non-functioning VP shunt, which 
was again successfully revised. The CSF showed almost normal 
polymorph and lymphocyte counts of 2 cells/μL and 6 cells/μL, 
respectively, and was microbiologically sterile. The last CT scan of the 
brain at the age of 28 months showed a functioning VP shunt with 
enhancement of the meninges and ventricles. The previous VP shunt 
tract indicated ventriculitis and inflammation, and signs of previously 
disseminated tuberculosis with residual calcifying tuberculomas. The 
anti-epileptic medication was changed from carbamazepine to sodium 
valproate. A day later the child’s mother, who was very ill, died as an 
inpatient owing to XDR-TB treatment failure, with dyspnoea, cyanosis 
and general malaise. Six days later (24 months on XDR-TB treatment), 
at the age of 28 months, the child died at a regional hospital, with 
persistent neurological symptoms consistent with a hydrocephalus and 
most likely a VP shunt infection. No autopsy was performed.
Discussion
In this case, transmission of XDR-TB bacilli from mother to 
child was not prevented. No specific measures to lower the risk 
of airborne transmission from mother to child are known to have 
been taken. There are no consistent recommendations to reduce 
airborne transmission from mothers with infectious drug-resistant 
tuberculosis to their newborns. Separation of mother and infant 
and masks for the mother are possible solutions.[5,6] In a low-income 
setting, it can be challenging to separate children from their mother 
and it is generally discouraged. Providing the mother with masks to 
wear during close contact with the child would have been feasible, 
but the effectiveness of non-fitted surgical masks in preventing 
transmission of droplet nuclei is largely unproven.[7] 
Prophylactic isoniazid treatment was given for only 3 months, 
whereas the guidelines recommend 6 months of treatment. However, 
it is unlikely that the reason for prophylaxis failure can be attributed to 
the treatment duration; it is most likely due to the failure of isoniazid 
to protect the child initially, allowing successful transmission while 
the child was on primary isoniazid prophylaxis. 
The primary isoniazid chemoprophylaxis was possibly ineffective, 
but evidence for a more appropriate regimen is lacking. Knowledge 
about the genetic mutation that causes isonazid resistance (inhA 
promoter gene or katG gene) is an insufficient basis for the decision 
to give normal- or high-dose isoniazid, as mutations in the katG 
gene can cause low-, middle- or high-level resistance to isoniazid.[8] 
Some experience with primary fluoroquinolone chemoprophylaxis is 
available from children exposed to multidrug-resistant tuberculosis 
(MDR-TB).[9] Any benefit of fluoroquinolones as primary chemo-
prophylaxis for persons exposed to XDR-TB is likely to be poorer 
than for MDR-TB. Reluctance to initiate potentially highly toxic 
drugs in an infant with no signs of tuberculosis, as required for 
primary chemoprophylaxis for drug-resistant tuberculosis exposure, 
is a comprehensible rationale.
Although the child was given XDR-TB treatment shortly after 
the first symptoms, she possibly died of the sequelae of meningitis 
(hydrocephalus with multiple VP shunt complications) after 2 years 
of treatment with a microbiologically appropriate (culture conversion 
of gastric lavage specimens) and clinically effective (weight gain and 
disappearance of inflammatory signs in the CSF) XDR-TB regimen. 
The underlying reason for the child developing XDR-TB (after 
strain acquisition, most probably from her mother) and the fatal 
outcome is most likely attributable to primary prevention failure 
with ensuing dissemination. This case highlights why early diagnosis 
with prompt initiation of appropriate treatment is so critical. Fatality 
from tuberculous meningitis rises from 5% to 80% when treatment 
is delayed for 5 weeks.[1] Appropriate treatment was started later than 
it could and should have been, even if the delay was not very long. 
When the child had a compensated hydrocephalus, only 
corticosteroids were administered as a medical therapy. Adjuvant 
furosemide and acetazolamide treatment for compensated hydro-
cephalus in children with tuberculous meningitis have been shown to 
have an effect on lowering of the intracranial pressure, but no effect on 
mortality or disability.[10] In this case, it is questionable whether adding 
these drugs would have had any effect on the outcome. Furthermore, 
these drugs were not tested in XDR-TB meningitis and in combination 
with corticosteroids.
Only a few reports have been published of children with central 
nervous system XDR-TB. While there are publications on poor 
outcomes of pre-XDR-TB and MDR-TB of the central nervous 
system,[11,12] there is also ground for some optimism demonstrated 
by the case of a 4-year-old girl in SA.[13] She had delayed treatment 
initiation and early onset of neurological symptoms, but recovered fully 
from XDR-TB meningitis after 18 months of adequate treatment.[13]
Several studies showed a positive effect of newer drugs, delamanid 
and bedaquiline, on the treatment success of XDR-TB, but insufficient 
data are available on their safety in children, and the discussion for 
their use as primary prophylaxis for high-risk infants has to our 
knowledge not yet begun.[14] In the time and context of this case, the 
newer drugs were not or scarcely available in SA. 
It is long known that early adequate treatment of tuberculosis 
can prevent the deleterious effects of dissemination, but it contrasts 
with our ignorance about effective prevention for complex drug-
resistant tuberculosis. This child’s case illustrates how important it 
is to act swiftly.
Teaching points
• If a neonate is exposed to XDR-TB, very frequent clinical assess-
ments and measures to lower the risk of airborne transmission are 
mandatory. This allows possible prevention and early detection 
of clinical manifestations that require an aggressive approach to 
diagnosis and treatment of tuberculosis, if indicated.
• Chemoprophylaxis must be administered according to the latest 
guidelines, in consultation with a specialised facility. 
• If a mother has XDR-TB, the child thought to have tuberculosis 
must be treated for XDR-TB – otherwise valuable time is wasted, 
potentially resulting in a disastrous outcome.
• The decisiveness of the approach must be adjusted to the infectivity 
potential of the index case.
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